Eight research analysts have assigned a buy rating to Pacira, and one gave the stock a hold rating. According to the report, the average 12-month target price among analysts that have issues ratings on the stock in the last year is $105.21.
Analysts across numerous research firms have recently improved Pacira’s ratings. Shares of Pacira were upgraded from “neutral” to “outperform” ratings, according to analysts at Zacks, and they currently have a $109.50 price target on the stock. Analysts at Wedbush and Canaccord Genuity have also raised their price target on shares of Pacira Pharmaceuticals, with Wedbush increasing stock prices from $98.00 to $110.00 and Canaccord Genuity up to $114.00.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
